Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Francisella tularensis LVS vaccine
- Development stage
- Unknown
- Lead developer
- DynPort Vaccine Company
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Scarification
01
Overview
The Francisella tularensis Live Vaccine Strain (LVS) vaccine is a live-attenuated bacterial vaccine developed for the prevention of tularemia, a potentially fatal zoonotic disease caused by the highly infectious bacterium *Francisella tularensis*. The LVS strain was originally derived from an attenuated *F. tularensis* subsp. *holarctica* strain. In the United States, it has been maintained as an Investigational New Drug (IND) by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) primarily for the protection of laboratory personnel and other high-risk individuals. The National Institute of Allergy and Infectious Diseases (NIAID) has collaborated with the DynPort Vaccine Company (DVC) to produce a new, standardized lot of the vaccine (DVC-LVS) using modern manufacturing practices to ensure consistency and safety. The vaccine is administered via scarification and works by inducing both cell-mediated and humoral immunity against the pathogen.
- Other names
- Tularemia LVS vaccineLive Vaccine Strain vaccineFrancisella tularensis live attenuated vaccine
Beyond the preview
Go deeper on Francisella tularensis LVS vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Francisella tularensis LVS vaccine.